U.S. markets closed

Keros Therapeutics, Inc. (KROS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
33.42-0.54 (-1.59%)
At close: 04:00PM EDT
33.42 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close33.96
Bid28.50 x 800
Ask41.80 x 900
Day's Range32.79 - 34.95
52 Week Range28.50 - 68.29
Avg. Volume149,725
Market Cap803.246M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-2.85
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for KROS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Keros Therapeutics, Inc.
    ITOS: What does Argus have to say about ITOS?ITEOS THERAPEUTICS INC has an Investment Rating of BUY; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • Benzinga

    Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial

    Keros Therapeutics Inc (NASDAQ: KROS) announced preliminary topline results from Part 1 of its Phase 1 trial evaluating single and multiple ascending doses of KER-012 in healthy postmenopausal volunteers. KER-012 was generally well tolerated in Part 1 at dose levels up to 5 mg/kg, the highest dose level tested when administered as a single dose. While one subject withdrew consent after receiving a single 1.5 mg/kg dose of KER-012 and did not complete the safety follow-up, there were no discontin

  • Benzinga

    Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure

    Keros Therapeutics Inc (NASDAQ: KROS) announced results from a preclinical study of RKER-012 in a mouse model of pulmonary arterial hypertension (PAH), a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The data were shared at the American Thoracic Society International Conference. RKER-012 prevented increased pulmonary arterial pressure and right ventricle hypertrophy in a rodent PAH model, and KER-012 did not alter red blood cell number in non

  • GlobeNewswire

    Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

    LEXINGTON, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced preliminary topline results from Part 1 of its Phase 1 clinical trial evaluating single and multiple ascending doses of KER-012 in healthy postmenopausal vol